Loading
For younger women, shutting down the ovaries and adding an aromatase inhibitor prevents more recurrences than tamoxifen alone, with the largest gains in the highest-risk women.
Combined 12-13-year analysis: exemestane + OFS improved DFS and distant recurrence-free interval over tamoxifen + OFS (absolute 4-5%) without an OS difference; SOFT 12-year: adding OFS to tamoxifen improved OS in the chemotherapy cohort (HR ~0.79). Basis for OFS in premenopausal women at higher risk.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
5,738 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| 12-year disease-free survival (TEXT+SOFT)primary | Exemestane + OFS | - | 80.5% | 0.79 (0.7 to 0.9) | - | link |
| Tamoxifen + OFS | - | 75.9% |
A second publication from the SOFT trial, later than the first and described in its title as an update or longer-term analysis. Read it with the primary publication linked from the trial page; the record was linked automatically and its figures have not been checked by hand.
This is the paper Europe PMC returns for registry id NCT00066690 with the most citations, so it is the natural first reading for anyone following the SOFT trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
Shares Exemestane, Letrozole (and other aromatase inhibitors), Tamoxifen, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test.
Shares Exemestane, Letrozole (and other aromatase inhibitors), Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, Endocrine therapy (SERMs, AIs, SERDs).
Shares Exemestane, Letrozole (and other aromatase inhibitors), Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs).
Shares Ovarian function suppression (OFS), Exemestane, Goserelin / leuprolide (ovarian function suppression), Letrozole (and other aromatase inhibitors).
Shares Ovarian function suppression (OFS), Exemestane, Goserelin / leuprolide (ovarian function suppression), Letrozole (and other aromatase inhibitors).
Shares High-risk early HR-positive breast cancer, Tamoxifen, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares High-risk early HR-positive breast cancer, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares High-risk early HR-positive breast cancer, Hormonal therapy roadmap: removing the ovaries → tamoxifen → oral degraders switched by a blood test, Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.